
Quotient Limited QTNT
Quarterly report 2023-Q3
added 05-23-2026
Quotient Limited Accounts Receivables 2011-2026 | QTNT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Quotient Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.27 M | 5.32 M | 4.54 M | 3.35 M | 2.86 M | 2.56 M | 2.27 M | 1.81 M | 2.44 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.27 M | 1.81 M | 3.49 M |
Quarterly Accounts Receivables Quotient Limited
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.65 M | 5.18 M | 5.06 M | 6.65 M | 6.15 M | 5 M | 4.45 M | 6.15 M | 4.54 M | 4.52 M | 5.97 M | 4.54 M | 5.04 M | 4.33 M | 4.72 M | 5.04 M | 2.36 M | 2.51 M | 2.88 M | 2.36 M | 2.51 M | 2.88 M | 2.86 M | 2.02 M | 2.02 M | 2.46 M | 2.8 M | 1.64 M | 1.48 M | 2.12 M | 2.21 M | 1.48 M | 2.01 M | 2.65 M | 3.23 M | 2.01 M | 2.65 M | 3.23 M | 2.44 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.65 M | 1.48 M | 3.56 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 204.05 | -0.23 % | $ 22.6 B | ||
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
84.8 M | $ 18.98 | 2.59 % | $ 584 M | ||
|
Co-Diagnostics
CODX
|
190 K | $ 4.22 | -6.22 % | $ 5.61 M | ||
|
Castle Biosciences
CSTL
|
43.4 M | $ 21.34 | 1.23 % | $ 619 M | ||
|
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.04 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
138 M | $ 130.56 | 0.33 % | $ 16.4 B | ||
|
CareDx, Inc
CDNA
|
42.6 M | $ 23.27 | 2.29 % | $ 1.24 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
ICON Public Limited Company
ICLR
|
1.47 B | $ 148.59 | -2.13 % | $ 11.7 B | ||
|
Illumina
ILMN
|
854 M | $ 163.32 | 2.06 % | $ 25.3 B | ||
|
Interpace Biosciences
IDXG
|
5.65 M | $ 1.76 | 1.32 % | $ 7.79 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
359 M | $ 102.45 | 2.47 % | $ 6.91 B | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 188.83 | -0.54 % | $ 9.36 B | ||
|
Medpace Holdings
MEDP
|
402 M | $ 471.6 | 1.03 % | $ 13.6 B | ||
|
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 131.19 | -2.73 % | $ 23.3 B | ||
|
NeoGenomics
NEO
|
159 M | $ 11.68 | 2.05 % | $ 1.5 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.63 | 1.87 % | $ 429 M | ||
|
National Research Corporation
NRC
|
11.1 M | $ 20.68 | 4.68 % | $ 463 M | ||
|
Natera
NTRA
|
297 M | $ 217.31 | -2.47 % | $ 29.7 B | ||
|
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.38 | 0.36 % | $ 414 M | ||
|
Personalis
PSNL
|
16.2 M | $ 9.81 | 0.56 % | $ 875 M | ||
|
Senseonics Holdings
SENS
|
127 K | $ 7.22 | -2.83 % | $ 301 M | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
28.2 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
731 K | $ 2.04 | -0.54 % | $ 4.69 M | ||
|
Twist Bioscience Corporation
TWST
|
57 M | $ 67.91 | -3.07 % | $ 4.06 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 271.33 | 0.05 % | $ 22.6 B | ||
|
Thermo Fisher Scientific
TMO
|
8.9 B | $ 484.82 | -1.87 % | $ 183 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
153 M | $ 9.19 | -1.13 % | $ 1.99 B | ||
|
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M |